EX-99.1 2 d289050dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Appendix 3B

New issue announcement

 

 

 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

 

Name of entity

 

Prima BioMed Ltd

 

ABN

 

90 009 237 889

 

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

  1

 

+Class of +securities issued or to be issued

   

 

Ordinary Shares

     

  2

 

Number of +securities issued or to be issued (if known) or maximum number which may be issued

   

 

1,538,462

     

  3

 

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

   

 

Pari passu with existing Ordinary Shares (PRR)

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 1


Appendix 3B

New issue announcement

 

 

 

  4

 

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

    the date from which they do

    the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

    the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

   

Yes (PRR)

     

  5

 

Issue price or consideration

   

Nil

 

     

  6

 

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

   

Issued upon vesting of unlisted performance rights issued on 29 December 2015 pursuant to the Prima BioMed Limited Executive Incentive Plan for the 2016 Short term Incentive offer following meeting the Key Performance Indications (KPI) and Service Conditions.

     

  6a

 

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

   

Yes, although these securities are not being issued under Listing Rule 7.1A

     

  6b

 

The date the security holder resolution under rule 7.1A was passed

   

25 November 2016

     

  6c

 

Number of +securities issued without security holder approval under rule 7.1

   

n/a

     

  6d

 

Number of +securities issued with security holder approval under rule 7.1A

   

n/a

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 2


Appendix 3B

New issue announcement

 

 

 

  6e

 

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

   

n/a

     

  6f

 

Number of +securities issued under an exception in rule 7.2

   

1,538,462 ordinary shares under exception 9(b)

     

  6g

 

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

   

n/a

     

  6h

 

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

   

n/a

     

  6i

 

Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

   

Refer Annexure 1

     

  7

 

+Issue dates

 

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

 

Cross reference: item 33 of Appendix 3B.

   

1 December 2016

     
     

Number

 

 

+Class

  8

 

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

   

2,073,076,271

 

77,378,693

 

Ordinary shares (ASX:

PRR)

 

Options exercisable at $0.20 on or before 19 June 2017 (PRRO)

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 3


Appendix 3B

New issue announcement

 

 

 

     

Number

 

+Class - Options

  9

  Number and +class of all     Amount   Exercise Price   Expiration Date
      1,515,752   $0.0774   30 June 2018
      165,116   $0.0774   30 June 2018
      147,628,500   $0.05019   12 December 2018
      371,445,231   $0.0237   4 August 2020
      793,103   $0.057   30 October 2020
      1,026,272   $0.040   7 March 2021
      8,475,995   $0.025   4 August 2025

 

      Number   +Class - Performance Rights
      Amount   Type   Expiration Date
      1,486,326   STI   5 August 2017
      30,918,333   LTI   30 October 2018
      20,666,667   PRs  

The PRs will expire between

30 days to 12 months

after the vesting date

of 5 August 2017

      857,844   NED PRs  

Each tranche of NED PRs will

expire 30 days from

each tranche vesting

date indicated in the

appendix 3B released

on 26 November

2014.

      13,750,828  

Convertible Notes each with a face value of

AU$1, expiring on 4 August 2025

 

  10

 

Dividend policy (in the case of a trust, distribution policy) on the

increased capital (interests)

  Unchanged

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 4


Appendix 3B

New issue announcement

 

 

 

 

Part 2 - Pro rata issue

 

       

  11

 

Is security holder approval required?

   

n/a

 

           

  12

 

Is the issue renounceable or non-renounceable?

   

n/a

           

  13

 

Ratio in which the +securities will be offered

   

n/a

           

  14

 

+Class of +securities to which the offer relates

   

n/a

           

  15

 

+Record date to determine entitlements

   

n/a

           

  16

 

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

   

n/a

       
           

  17

 

Policy for deciding entitlements in relation to fractions

   

n/a

       
           

  18

 

Names of countries in which the entity has security holders who will not be sent new offer documents

 

Note: Security holders must be told how their entitlements are to be dealt with.

 

Cross reference: rule 7.7.

   

n/a

           

  19

 

Closing date for receipt of acceptances or renunciations

   

n/a

 

           

  20

 

Names of any underwriters

   

n/a

 

           

  21

 

Amount of any underwriting fee or commission

   

n/a

 

           

  22

 

Names of any brokers to the issue

   

n/a

           

  23

 

Fee or commission payable to the broker to the issue

   

n/a

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 5


Appendix 3B

New issue announcement

 

 

 

         

  24

 

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

   

n/a

         

  25

 

If the issue is contingent on security holders’ approval, the date of the meeting

   

n/a

       
         

  26

 

Date entitlement and acceptance form and offer documents will be sent to persons entitled

   

n/a

       
         

  27

 

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

   

n/a

       
         

  28

 

Date rights trading will begin (if applicable)

   

n/a

 

       
             

  29

 

Date rights trading will end (if applicable)

   

n/a

 

       
         

  30

 

How do security holders sell their entitlements in full through a broker?

   

n/a

       
         

  31

 

How do security holders sell part of their entitlements through a broker and accept for the balance?

   

n/a

       
         

  32

 

How do security holders dispose of their entitlements (except by sale through a broker)?

   

n/a

       
         

  33

 

+Issue date

   

n/a

 

       

 

Part 3 - Quotation of securities

   

You need only complete this section if you are applying for quotation of securities

 

 

  34        

Type of +securities

(tick one)

       
  (a)  

x

 

   

+Securities described in Part 1

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 6


Appendix 3B

New issue announcement

 

 

 

  (b)

 

¨

   

All other +securities

 

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

 

Entities that have ticked box 34(a)

 

 

Additional securities forming a new class of securities

 

Tick to indicate you are providing the information or documents

       

  35

 

¨

   

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

       

  36

 

¨

   

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

       
  37      

¨

 

   

A copy of any trust deed for the additional +securities

 

Entities that have ticked box 34(b)

 

  38  

Number of +securities for which +quotation is sought

   

n/a

     
  39  

+Class of +securities for which quotation is sought

   

n/a

     
  40  

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

    the date from which they do

    the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

    the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

   

n/a

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 7


Appendix 3B

New issue announcement

 

 

 

  41

 

Reason for request for quotation now

 

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another +security, clearly identify that other +security)

   

n/a

   
       
     

Number

 

+Class

  42    

 

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

   

n/a

   

Quotation agreement

 

1

+Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2

We warrant the following to ASX.

 

   

The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

   

There is no reason why those +securities should not be granted +quotation.

 

   

An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

   

Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

+ See chapter 19 for defined terms.

    
04/03/2013    Appendix 3B Page 8      


Appendix 3B

New issue announcement

 

 

 

 

   

If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3

We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

Sign here:

     

LOGO

     

Date: 1 December 2016

     

Company Secretary

     

Print name:

     

Tom Bloomfield

     

== == == == ==

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 9


Appendix 3B

New issue announcement

 

 

 

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

 

 

Rule 7.1 – Issues exceeding 15% of capital

 

 

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

 

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

 

      

 

2,058,297,608

 

Add the following:

 

        

 

•    Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

      

 

  14,778,663

 

•    Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

        

 

•    Number of partly paid +ordinary securities that became fully paid in that 12 month period

 

Note:

•    Include only ordinary securities here – other classes of equity securities cannot be added

•    Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

•    It may be useful to set out issues of securities on different dates as separate line items

 

        

 

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

 

      

 

  Nil

 

“A”

 

      

 

2,073,076,271

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 10


Appendix 3B

New issue announcement

 

 

 

 

Step 2: Calculate 15% of “A”

 

 

“B”

      

 

0.15

 

[Note: this value cannot be changed]

 

 

Multiply “A” by 0.15

 

      

 

310,961,441

 

 

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

 

 

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

 

•    Under an exception in rule 7.2

 

•    Under rule 7.1A

 

•    With security holder approval under rule 7.1 or rule 7.4

 

Note:

•    This applies to equity securities, unless specifically excluded – not just ordinary securities

•    Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

•    It may be useful to set out issues of securities on different dates as separate line items

 

      

 

1,026,272

 

“C”

 

      

 

1,026,272

 

 

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

 

 

“A” x 0.15

 

Note: number must be same as shown in Step 2

 

      

 

310,961,441

 

Subtract “C”

 

Note: number must be same as shown in Step 3

 

      

 

1,026,272

 

Total [“A” x 0.15] – “C”

      

 

309,935,169

 

[Note: this is the remaining placement capacity under rule 7.1]

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 11


Appendix 3B

New issue announcement

 

 

 

Part 2

 

 

Rule 7.1A – Additional placement capacity for eligible entities

 

 

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

 

“A”

 

Note: number must be same as shown in Step 1 of Part 1

 

 

 

2,073,076,271

 

Step 2: Calculate 10% of “A”

 

 

“D”

 

 

0.10

 

Note: this value cannot be changed

 

 

Multiply “A” by 0.10

 

 

 

207,307,627

 

 

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

 

 

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

 

Notes:

•    This applies to equity securities – not just ordinary securities

•    Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

•    Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

•    It may be useful to set out issues of securities on different dates as separate line items

 

 

 

nil

 

“E”

 

 

 

nil

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 12


Appendix 3B

New issue announcement

 

 

 

 

 

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A

 

 

“A” x 0.10

 

Note: number must be same as shown in Step 2

 

  

 

207,307,627

 

Subtract “E”

 

Note: number must be same as shown in Step 3

 

  

 

nil

 

Total [“A” x 0.10] – “E”

  

 

207,307,627

 

Note: this is the remaining placement
capacity under rule 7.1A

 

 

+ See chapter 19 for defined terms.

    

04/03/2013

   Appendix 3B Page 13